Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7335275 | 0.88 | MPO (0.49) | TAAR1HSPA5HTR1AMPOTSHR | |
| SCHEMBL118255 | 0.85 | TAAR1 (0.54) | TAAR1HSPA5HTR1AMPOTSHR | |
| 1-Hexanol SCHEMBL27501536 | 0.84 | HTR1A (0.43) | TAAR1HTR1ATSHRALDH1A1TDP1 | |
| SCHEMBL10442033 | 0.82 | TAAR1 (0.55) | TAAR1HSPA5HTR1AMPOTSHR | |
| SCHEMBL4779473 | 0.79 | TSHR (0.50) | TAAR1HSPA5HTR1AMPOTSHR | |
| SCHEMBL21483748 | 0.78 | HSPA5 (0.52) | TAAR1HSPA5HTR1AMPOTSHR | |
| SCHEMBL5292044 | 0.78 | TAAR1 (0.50) | TAAR1TSHRCYP2D6IDO1ALDH1A1 | |
| SCHEMBL7117302 | 0.77 | MPO (0.49) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL18699330 | 0.77 | TAAR1 (0.46) | TAAR1HSPA5HTR1AMPOTSHR | |
| SCHEMBL27873337 | 0.77 | AKR1B1 (0.50) | TAAR1HSPA5HTR1AMPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492177-B2 | RAR-α compounds for inflammatory disease and male contraception | Orphagen Pharmaceuticals, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| CN-115335367-B | RAR-alpha compounds for inflammatory diseases and male contraception | 奥弗恩制药公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. | 2023-11-09 | — | — | US | disclosed |
| CN-115335367-A | RAR-alpha compounds for use in inflammatory diseases and male contraception | 奥弗恩制药公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4077300-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127250-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127250-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| CN-1145619-A | Substituted pyridine leukotriene B4 antagonists | HOFFMANN LA ROCHE (CH) | 1997-03-19 | — | — | CN | disclosed |
| US-5563148-A | BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0307172-B1 | Improvements in or relating to specific 5-HT3 antagonists | LILLY CO ELI (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5442078-A | Intermediates for specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5364863-A | Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0435681-A1 | Chroman esters of phenols and benzoic acids having retinoid-like activity | ALLERGAN, INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| US-5006550-A | Skin disorder, arthritis, wound healing agents, dry eye syndrome | ALLERGAN, INC. (US) | 1991-04-09 | — | — | US | disclosed |
| US-4997956-A | Analgesics | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
| US-4921982-A | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | RARA, RARB, RARG | TAAR1 971/4885HSPA5 2389/4885HTR1A 1942/4885 |
| US-12492177-B2 | RAR-α compounds for inflammatory disease and male contraception | RARA, RARB, RARG | TAAR1 974/4885HSPA5 2392/4885HTR1A 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.